RxDoctor Payments Data

Alex Schaffer

Optometrist · Setauket, NYNPI 1538476171

Payments from drug & device makers

$2,443in general payments, 2019–2025

Across 104 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$486
  • Sun Pharmaceutical Industries Inc.$284
  • Tarsus Pharmaceuticals, Inc.$228
  • NEW World Medical,inc.$224
  • Alcon$194
  • Harrow Eye, LLC$184
  • plus $842 from 14 others

What the payments were for

  • Food & beverage$2,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,443 in reported general payments places this provider in the 80th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$254,803
Medicare patients
961
Services billed
2,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine17$24,572
Cyclosporine16$11,941
LumiganBimatoprost19$9,660
Tobramycin-DexamethasoneTobramycin/Dexamethasone159$7,156
Prednisolone Acetate23$737
Fluorometholone11$672
Ofloxacin40$478
Ketorolac Tromethamine16$459
Brimonidine Tartrate39$458
ErythromycinErythromycin Base22$289
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$269
Latanoprost24$234
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$225
Dorzolamide Hcl11$163
Timolol Maleate14$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$47$34,23236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,743 optometrist providers in New York.

Other optometrist in Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →